Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $14.91 USD
Change Today +0.63 / 4.41%
Volume 1.8M
FOLD On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 09/2/15 All times are local (Market data is delayed by at least 15 minutes).

amicus therapeutics inc (FOLD) Snapshot

Open
$14.70
Previous Close
$14.28
Day High
$14.92
Day Low
$14.23
52 Week High
08/5/15 - $18.83
52 Week Low
10/15/14 - $5.13
Market Cap
1.8B
Average Volume 10 Days
1.9M
EPS TTM
$-0.98
Shares Outstanding
118.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AMICUS THERAPEUTICS INC (FOLD)

amicus therapeutics inc (FOLD) Related Bloomberg News

View More Bloomberg News

amicus therapeutics inc (FOLD) Related Businessweek News

No Related Businessweek News Found

amicus therapeutics inc (FOLD) Details

Amicus Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapeutic products for rare and orphan diseases. Its product candidate is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The company’s development programs include next-generation ERTs for lysosomal storage disorders (LSDs), such as Fabry disease, Pompe disease, and Mucopolysaccharidosis Type I. It also develops pharmacological chaperone migalastat HCl as a monotherapy that has completed two Phase III global registration studies for Fabry disease; ATB200, a recombinant human acid-alpha glucosidase that is in late preclinical development for Pompe disease; and AT3375 for the treatment of Parkinson's disease. The company has strategic collaboration with GlaxoSmithKline PLC to develop and commercialize migalastat. Amicus Therapeutics, Inc. was incorporated in 2002 and is based in Cranbury, New Jersey.

97 Employees
Last Reported Date: 03/3/15
Founded in 2002

amicus therapeutics inc (FOLD) Top Compensated Officers

Chairman and Chief Executive officer
Total Annual Compensation: $1.1M
President and Chief Operating Officer
Total Annual Compensation: $635.0K
Chief Financial Officer and Secretary
Total Annual Compensation: $568.6K
Chief Medical Officer
Total Annual Compensation: $707.1K
Vice President of Legal & Intellectual Proper...
Total Annual Compensation: $418.2K
Compensation as of Fiscal Year 2014.

amicus therapeutics inc (FOLD) Key Developments

Amicus Therapeutics, Inc., Scioderm, LLC - M&A Call

To discuss the agreement under which Amicus will acquire 100% of the capital stock of Scioderm, Inc

Amicus Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Financial Guidance for the Full Year of 2015

Amicus Therapeutics, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported loss from operations of $26,943,000, net loss of $27,133,000 or $0.27 per basic and diluted share against loss from operations of $14,266,000, net loss of $14,614,000 or $0.22 per basic and diluted share a year ago. The wider net loss is primarily attributed to an increase in operating expenses. For the six months, the company reported loss from operations of $51,001,000, net loss of $51,421,000 or $0.53 per basic and diluted share against loss from operations of $29,887,000, net loss of $30,557,000 or $0.46 per basic and diluted share a year ago. The company continues to expect full-year 2015 net cash spend between $100 million and $110 million. The current cash position is projected to fund operations into 2017.

Amicus Therapeutics, Inc. to Report Q2, 2015 Results on Aug 05, 2015

Amicus Therapeutics, Inc. announced that they will report Q2, 2015 results on Aug 05, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FOLD:US $14.91 USD +0.63

FOLD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FOLD.
View Industry Companies
 

Industry Analysis

FOLD

Industry Average

Valuation FOLD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4,873.4x
Price/Book 5.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4,547.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMICUS THERAPEUTICS INC, please visit www.amicustherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.